NOI - Next Generation Sequencing Services for Detection of Somatic Genetic Mutations
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Heart, Lung, and Blood Institute (NHLBI) intends to award a sole source purchase order to Genomic Testing Cooperative (GTC) for Next Generation Sequencing (NGS) services. This Notice of Intent (NOI) is for detecting somatic genetic mutations in patient samples to support clinical research on bone marrow failure syndromes and hematologic disorders. Interested parties may submit a capability statement for consideration.
Purpose & Scope
NHLBI requires specialized NGS services to analyze patient samples for somatic genetic mutations associated with bone marrow failure syndromes and hematologic disorders. These services are vital for clinical diagnosis, therapeutic strategy determination, and ongoing clinical research. The scope includes analyzing approximately 302 genes, isolating nucleic acids from various sample types (plasma, fresh cells, FFPE tissue), performing massive parallel sequencing of coding DNA regions, and detecting mutations (insertions, deletions, structural variants). Fragment length analysis for specific genes (e.g., CALR, FLT3, NPM1) is also required. Services must accommodate low DNA input, provide secure electronic results, and maintain a turnaround time of 7-10 days for approximately 16 samples.
Contract Details
This is a pre-solicitation Notice of Intent for a sole source purchase order, not a request for competitive proposals. The contract will be awarded under FAR Part 13 (Simplified Acquisition Procedures) and FAR Part 12 (Acquisition of Commercial Products and Commercial Services). The period of performance will continue until all samples are processed.
Set-Aside & Eligibility
This acquisition is NOT set aside for small business. The applicable NAICS code is 541380 – Testing Laboratories and Services, with a size standard of $19 million. The government has determined GTC is uniquely capable due to a specific sequencing panel, faster turnaround time, and the need for continuity with existing longitudinal data.
Submission & Deadline
While this is a sole source NOI, interested parties may submit a capability statement demonstrating their ability to meet the stated requirements. Responses should include unit price, list price, shipping and handling costs, delivery period, prompt payment terms, F.O.B. Point, DUNS number, TIN, and certification of business size. All offerors must have an active registration in the System for Award Management (SAM). Capability statements must be submitted electronically to nicholas.capobianco@nih.gov by April 20, 2026, at 4:00 PM EDT.